Ehrly AM: Influence of Arvin on the flow properties of
blood. Biorheology9:151, 1972.
2.
Lowe Gdo, Reavey MM, Johnston RV, et al: Increased platelet aggregates in vascular and
non-vascular illness: Correlation with plasma fibrinogen and effect of
ancrod. Thromb Res14:377, 1979.
3.
Ehringer H., Dudczek R., Lechner K.: A new approach in the treatment of peripheral arterial
occlusions: Defibrination with Arvin. Abstracts of Fourth International Congress
onThrombosis and Haemostasis, Vienna,
1973, p. 279.
4.
Ehrly AM, Schroeder W.: Oxygen pressure in ischaemic muscle tissue of patients with
chronic occlusive arterial diseases. Angiology,
28:101, 1977.
5.
Dormandy JA, Goyle KB, Reid HL: Treatment of severe intermittent claudication by controlled
defibrination . Lancet1:625, 1977.
6.
Meissner AJ, Karpowicz M., Koropka L., Lopaciuk S.: Changes in the muscle rest blood flow associated with
therapeutic defibrinogenation . Abstracts of
Seventeenth Congress of International Society of Hematology,
Paris, 1977, p. 326.
7.
Lowe Gdo, Morrice JJ, Forbes CD, et al: Subcutaneous ancrod therapy in peripheral arterial
disease — improvement in blood viscosity and nutritional blood
flow. Angiology, in the press.
8.
Martin M., Hirdes G., Auel H.: Defibrinogenation treatment in patients suffering from severe
intermittent claudication — a controlled study. Thromb
Res9:47, 1976.
9.
Wolf GK: Arwin in peripheral arterial circulatory disorders:
Controlled multicentre trials. Eur J Clin Pharm9:387, 1976.
10.
Yao Jst: New techniques in objective arterial
evaluation. Arch Surg106:600, 1973.
11.
Clauss A.: Gerinnungsphysiologische Schnellmethode zur Bestimmung des
Fibrinogens. Acta Haematol17:237, 1957.
12.
Armitage P.: Statistical Methods in Medical Research.
Blackwell, Oxford,
U. K., 1975.
